Evidence map›Paper›PMID 36341340›Full record

ArticleFrontiers in immunology2022

Bioengineering and computational analysis of programmed cell death ligand-1 monoclonal antibody.

Muhammad Kalim, Hamid Ali, Ashfaq Ur Rehman, Yong Lu, Jinbiao Zhan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Muhammad KalimDepartment of Biochemistry and Cancer Institute of the Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Hamid AliDepartment of Biosciences, COMSATS University, Islamabad, Pakistan.
Ashfaq Ur RehmanDepartment of Molecular Biology and Biochemistry, University of California, Irvine, Irvine, CA, United States.
Yong LuLaboratory of Minigene Pharmacy, School of Life Science and Technology, China Pharmaceutical University, Tongjia Xiang, Nanjing, China.
Jinbiao ZhanDepartment of Biochemistry and Cancer Institute of the Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Second Affiliated Hospital of Zhejiang University · CNChina Pharmaceutical University · CNCOMSATS University Islamabad · PKUniversity of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The trans-membrane proteins of the B7 family programmed cell death ligand-1 (PD-L1) and programmed death-1 (PD-1) play important roles in inhibiting immune responses and enhancing self-tolerance

Indexed as

Antibodies, MonoclonalB7-H1 AntigenAnimalsApoptosisBioengineeringLigandsMammalsProgrammed Cell Death 1 ReceptorAntibodies, MonoclonalB7-H1 AntigenLigandsProgrammed Cell Death 1 Receptorchimeramonoclonal antibodyPD-L1protein-protein interactionrecombinant technology

Identifiers

PMID36341340
PMCPMC9633666
OpenAlexW4306952021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.